Pricing and reimbursement remain national decisions in the EU, but they are no longer taken in isolation. Since the mid-2010s, groups of Member States have pooled horizon scanning, health technology assessment and, in some cases, price negotiations. Greece is part of one of these groups, the Valletta Declaration. For companies planning a Greek launch, it helps to understand what these alliances do, what they have actually delivered, and how they sit alongside the EU HTA Regulation.
The three main alliances
- Beneluxa Initiative. Launched in 2015 by Belgium, the Netherlands and Luxembourg, later joined by Austria and Ireland. It covers horizon scanning, joint HTA, information sharing and pricing and reimbursement. Its first joint assessment and negotiation, for nusinersen, was concluded in 2018. Multi-country reimbursement agreements have since followed for onasemnogene abeparvovec and atidarsagene autotemcel.
- Nordic cooperation. The FINOSE collaboration between Finland, Norway and Sweden became the Joint Nordic HTA-Bodies (JNHB) in 2024, bringing in HTA bodies from all five Nordic countries. Separately, the Nordic Pharmaceuticals Forum has worked on joint procurement and price negotiations.
- Valletta Declaration. Signed in Malta in 2017 and now covering ten Southern and Central European countries, including Greece, Cyprus, Italy, Spain and Portugal. Its stated aims include horizon scanning, sharing pricing information, joint assessment and joint negotiation for selected medicines.
What has actually been achieved
Results so far are uneven. Beneluxa has the clearest track record: around 15 joint HTA reports and four joint negotiations in its first decade, three of which ended in multi-country agreements. Most concerned high-cost therapies for rare diseases, where small national populations make shared evidence review and pooled bargaining most attractive.
The Valletta group has published far less about completed joint deals. Its main value for companies is less a single shared price than a network for exchanging information. Payers in member countries can compare evidence, negotiation positions and, potentially, confidential pricing terms, which makes inconsistent submissions or contradictory claims easier to spot.
How this fits with the EU HTA Regulation
Regulation (EU) 2021/2282 has applied since 12 January 2025. It introduces Joint Clinical Assessments (JCA) for new oncology medicines and ATMPs, extending to orphan medicines from January 2028 and to all centrally authorised new medicines from 2030. JCA covers only the clinical domain. Economic evaluation, pricing and reimbursement stay with Member States, and that is exactly the space the voluntary alliances occupy. In practice, a company may face an EU-level clinical assessment, an alliance-level exchange of information, and a national decision by the Greek HTA Committee and Negotiation Committee.
Practical implications for companies launching in Greece
- Consistency across markets. Assume that your value narrative, comparators and evidence gaps may be visible to payers in several countries at once. Keep dossiers aligned with each other and with the JCA report.
- Launch sequencing. Greece already uses external reference pricing. Alliance information sharing adds another reason to plan list prices, confidential discounts and managed entry terms as one European strategy rather than country by country.
- Rare disease and one-off therapies. These are the most likely candidates for joint work. Prepare early for questions on budget impact, outcomes-based agreements and data collection that would work across several health systems.
- Horizon scanning visibility. Payers increasingly see pipelines years ahead. Early, consistent engagement with the authorities is more valuable than a late, polished submission.
How PQRA helps
PQRA supports pharmaceutical companies with market access strategy for Greece in its European context. We help align HTA dossiers with JCA outputs, prepare submissions to the Greek HTA and Negotiation Committees, model budget impact, and design pricing and managed entry approaches that hold up when compared across borders.
Contact PQRA to discuss your market access strategy for Greece and Europe →


No responses yet